Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Medical History Risk Factors in Primary Progressive Multiple Sclerosis: A Case-Control Study



Maroufi H1 ; Moghadasi AN1 ; Rezaeialiabadi H2 ; Sahraian MA1 ; Eskandarieh S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Bam University of Medical Sciences, Bam, Iran

Source: Current Journal of Neurology Published:2021

Abstract

Background: The association between medical history and primary progressive multiple sclerosis (PPMS) development has not been well documented in the pertinent literature. The possible association between 23 medical diseases and PPMS occurrence was assessed in the present study. Methods: In order to figure out the possible association between several medical histories and PPMS occurrence, the present population-based case-control study examined 143 PPMS cases in Tehran, Iran, from 2019 to 2020. Diagnosis of PPMS was confirmed by neurologists based on the 2017 McDonald criteria. Sex-matched healthy controls (n = 143) were selected using the random-digit dialing (RDD) technique. Face-to-face and telephone interviews were conducted for gathering the data. The conditional logistic regression model was used to calculate adjusted and unadjusted odds ratio (OR) at a 95% confidence interval (CI). Results: A significant association was found between PPMS development and diseases like depression (OR = 3.12, 95% CI: 1.49-6.53), migraine (OR = 0.19, 95% CI: 0.05-0.67), infectious mononucleosis (OR = 13.16, 95% CI: 2.74-63.17), hypothyroidism (OR = 3.20, 95% CI: 1.23-8.30), and kidney failure (OR = 3.76, 95% CI: 1.41-9.99). Conclusion: Lifetime history of depression, infectious mononucleosis, hypothyroidism, and kidney failure might increase the risk of PPMS development, while individuals with positive history of migraine disease are at lower risk for developing PPMS. © 2021 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Environmental Risk Factors of Multiple Sclerosis in the Middle East and North Africa Region: A Systematic Review, Current Journal of Neurology (2021)
2. Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study, Neuroepidemiology (2019)
3. Dietary Risk Factors of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2021)
4. Determining the Effect of Sun Exposure and Physical Activity on the Incidence of Primary Progressive Multiple Sclerosis, Tehran University Medical Journal (2022)
5. Waterpipe and Cigarette Smoking and Drug and Alcohol Consumption, and the Risk of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Current Journal of Neurology (2023)
6. Environmental Risk Factors of Late-Onset Multiple Sclerosis: A Population-Based Case-Control Study, Journal of Clinical Neuroscience (2025)
7. Environmental Risk Factors in Neuromyelitis Optica Spectrum Disorder: A Case–Control Study, Acta Neurologica Belgica (2018)
8. Stressful Life Events and the Risk of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2021)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (34)
Sharareh Eskandarieh (16)
Other Related Docs
9. The Association Between Multiple Sclerosis and Migraine: A Meta-Analysis, Multiple Sclerosis and Related Disorders (2023)
10. Multiple Sclerosis Projection in Tehran, Iran Using Bayesian Structural Time Series, BMC Neurology (2021)
11. Infectious Exposure, Antibiotic Use, and Multiple Sclerosis: A Population-Based Incident Case-Control Study, Acta Neurologica Scandinavica (2018)
12. The Role of Dietary Antioxidant Index and Index of Nutritional Quality in Ms Onset: Finding From an Iranian Population-Based Incident Case–Control Study, Nutritional Neuroscience (2022)
13. Smoking and Worsening Disability in Multiple Sclerosis: A Meta-Analysis, Acta Neurologica Scandinavica (2018)
14. The Role of Nutritional Factors During Adolescence in Multiple Sclerosis Onset: A Population-Based Incident Case–Control Study, Nutritional Neuroscience (2021)
15. Dietary Inflammatory Index and Risk of Multiple Sclerosis: Findings From a Large Population-Based Incident Case–Control Study, Clinical Nutrition (2020)
16. Stressful Life Events, Socioeconomic Status, and the Risk of Neuromyelitis Optica Spectrum Disorder: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2020)
17. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
18. Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020), Multiple Sclerosis and Related Disorders (2022)
19. Mri Features and Disability in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Journal of Neuroradiology (2024)
20. The Epidemiologic Trend of Multiple Sclerosis in Razavi Khorasan Province, Iran in Fifteen-Year Period, Multiple Sclerosis and Related Disorders (2025)
21. No Association Between Socioeconomic Status and Risk of Multiple Sclerosis: A Population-Based Incident Case-Control Study in a Developing Country, Multiple Sclerosis and Related Disorders (2018)
22. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
23. Estimating the Marginal Causal Effect of Fish Consumption During Adolescence on Multiple Sclerosis: A Population-Based Incident Case-Control Study, Neuroepidemiology (2018)
24. Socioeconomic Determinants of Global Distribution of Multiple Sclerosis: An Ecological Investigation Based on Global Burden of Disease Data, BMC Neurology (2021)
25. Waterpipe Smoking Associated With Multiple Sclerosis: A Population-Based Incident Case–Control Study, Multiple Sclerosis (2017)
26. Effectiveness of Repetitive Transcranial Magnetic Stimulation (Rtms) Add-On Therapy to a Standard Treatment in Individuals With Multiple Sclerosis and Concomitant Symptoms of Depression—Results From a Randomized Clinical Trial and Pilot Study, Journal of Clinical Medicine (2023)
27. Rna Sequencing of Cd4+ T Cells in Relapsing–Remitting Multiple Sclerosis Patients at Relapse: Deciphering the Involvement of Novel Genes and Pathways, Journal of Molecular Neuroscience (2021)
28. Comparing Epidemiology and Baseline Characteristic of Multiple Sclerosis and Neuromyelitis Optica: A Case-Control Study, Multiple Sclerosis and Related Disorders (2017)
29. Stress-Full Life Events and Multiple Sclerosis: A Population-Based Incident Case-Control Study, Multiple Sclerosis and Related Disorders (2018)
30. Uncovering the Causal Link Between Obesity-Associated Genes and Multiple Sclerosis: A Systematic Literature Review, Brain and Behavior (2025)
31. The Effects of Different Types of Smoking on Recovery From Attack in Hospitalized Multiple Sclerosis Patients, Clinical Neurology and Neurosurgery (2023)
32. Parental Smoking Before Childbirth and Multiple Sclerosis Onset in Their Child: A Case-Control Study, Acta Neurologica Belgica (2025)
33. Differential Serostatus of Epstein-Barr Virus in Iranian Ms Patients With Various Clinical Patterns, Medical Journal of the Islamic Republic of Iran (2018)
34. The Health Burden of Non-Communicable Neurological Disorders in the Usa Between 1990 and 2017, Brain Communications (2020)
35. Prevalence and Incidence of Multiple Sclerosis in Ardabil, Northwest of Iran, Multiple Sclerosis and Related Disorders (2021)
36. Lifestyle Factors and Multiple Sclerosis: A Population-Based Incident Case-Control Study, Multiple Sclerosis and Related Disorders (2018)
37. Impact of Alcohol Consumption on Multiple Sclerosis Using Model-Based Standardization and Misclassification Adjustment Via Probabilistic Bias Analysis, Archives of Iranian Medicine (2023)
38. Widespread Disruptions of White Matter in Familial Multiple Sclerosis: Dti and Noddi Study, Frontiers in Neurology (2021)
39. Multiple Sclerosis Pathogenesis: Missing Pieces of an Old Puzzle, Reviews in the Neurosciences (2019)
40. The Effects of Mannuronic Acid on Il-1Β, Il-17A, Stat1, and Stat3 Gene Expressions and Tlr2 and Tlr4 Molecules in Multiple Sclerosis, Journal of Clinical Pharmacology (2022)
41. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)
42. Parental Ethnicity Associated With Risk for Multiple Sclerosis: A Population-Based Incident Case–Control Study in Iran, Multiple Sclerosis and Related Disorders (2018)
43. Neuroscience20 (Brain20, Spine20, and Mental20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies, Journal of Alzheimer's Disease (2021)
44. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
45. Exploring Autoimmune Endocrine Diseases Induced by Monoclonal Antibodies Used As Multiple Sclerosis Pharmacotherapy: A Systematic Review, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
46. Comparing Cognitive Impairment Using Macfims in Patients With Multiple Sclerosis and Healthy Controls: A Systematic Review and Meta-Analysis, BMC Neurology (2024)
47. Exome Sequencing Reveals Novel Rare Variants in Iranian Familial Multiple Sclerosis: The Importance of Pold2 in the Disease Pathogenesis, Genomics (2021)
48. The Prevalence of Inflammatory Bowel Disease (Ibd) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2023)
49. Efficacy of Disease Modifying Therapies in Progressive Ms and How Immune Senescence May Explain Their Failure, Frontiers in Neurology (2022)
50. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)